Prosecution Insights
Last updated: November 04, 2026
Application No. 18/866,129

METHOD AND APPARATUS FOR CLASSIFYING WHITE BLOOD CELLS

Non-Final OA §101§102§103§112
Filed
Nov 15, 2024
Priority
May 17, 2022 — EU 22173796.8 +1 more
Examiner
MARTIN, PAUL C
Art Unit
1653
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Meon Functional Diagnostics GmbH & Co. Kg
OA Round
1 (Non-Final)
42%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
64%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
347 granted / 831 resolved
-18.2% vs TC avg
Strong +22% interview lift
Without
With
+21.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
63 currently pending
Career history
899
Total Applications
across all art units

Statute-Specific Performance

§101
5.7%
-34.3% vs TC avg
§103
53.6%
+13.6% vs TC avg
§102
11.4%
-28.6% vs TC avg
§112
20.6%
-19.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 831 resolved cases

Office Action

§101 §102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-15 are pending in this application. Election/Restrictions Applicant’s election without traverse of Group I (Claims 1-13) in the reply filed on 09/10/2026 is acknowledged. Claims 14-15 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/10/2026. Claims 1-13 were examined on their merits. Claim Interpretation Claim 9 contains an optional limitation. The broadest, reasonable interpretation of an optional limitation is that it is not required, and the claim has been construed thusly. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 4, 9, 10, 11, 12 and 13 are rejected under 35 U.S.C. § 112(b) or 35 U.S.C. §112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claims 2, 4, 10, 11, 12 and 13, the phrases "preferably" and “especially” render the claims indefinite because it is unclear whether the limitation(s) following the phrases are part of the claimed invention. See MPEP § 2173.05(d). Claim 7 recites, “wherein the COT [centroid-of-trajectory] corresponds to the centroid of the trajectory”. This appears to be redundant as a centroid-of-trajectory will necessarily correspond to itself. Claim 9 recites the limitation "the predetermined color space map". There is insufficient antecedent basis for this limitation in the claim. Claim 9 recites “said cluster”. It is unclear if this refers to the cluster of COTs or the clusters assigned to an area of the predetermined color space. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 1 and 6-13 are rejected under 35 U.S.C. § 101 because the claimed invention is directed to Judicial Exception(s) without significantly more. The claim(s) recite(s) Abstract Ideas and/or Mental processes. These judicial exceptions are not integrated into a practical application because they amount to a general linkage of the use of the JEs to a particular technological environment/field of use, that is, classifying white blood cells. The claim(s) does/do not include additional elements that are sufficient to amount to significantly more than the judicial exception because of the following analysis: Step 1) The claims are drawn to a process Step 2A, P1) The claims recite the Judicial Exception of Abstract Ideas. Claim 1 recites, "analyzing", "to classify" and “by extracting”; Claims 6 and 7 recite, “analyzing” and "determining"; Claim 8 recites, “analyzing”, "assigning" and “classifying”; Claim 9 recites, “clustering”, "assigning", "determining", “are classified” and "classifying"; Claim 10 recites, “creating”, “scaling”, "aligning", “are classified”, “classifying” and "assigning"; Claim 11 recites, “are selected”; Claim 12 recites, “are classified”; and Claim 13 recites “counting”, “determining” and “for obtaining”. Step 2A, P2) These judicial exceptions are not integrated into a practical application because they amount to a general linkage of the use of the JEs to a particular technological environment/field of use, that is, classifying white blood cells. Step 2B) The claims do not recite additional elements that amount to significantly more than the JEs. Claim 1 recited "providing a sample comprising a plurality of white blood cells", “adding at least one luminescent dye to the sample, thereby staining the white blood cells”, “disposing the stained white blood cells on a test surface”, “recording a luminescence image series of the stained white blood cells at a plurality of different timepoints wherein each luminescence image comprises at least a first and second color channel” and “for each white blood cell of the plurality, obtaining a luminescence data series” which are recited with a high degree of generality, are mere data gathering, and are well-known and routine in the white blood cell differential art. See for example, Powless et al. (2017), cited in the IDS, whom teaches a method comprising providing a blood sample (inherently comprising a plurality of white blood cells/WBCs), adding a luminescent dye (acridine orange) to the sample to stain the WBCs, placing the stained WBCs on a test surface (epi-fluorescence microscope) and recording a series of images over-time in a first (red) and second color (green) channel (thereby obtaining a data series for each white blood cell) and, analyzing the data to classify the WBC into predetermined categories (lymphocyte/monocyte/granulocyte) (Pg. 3, Paragraph 2.2, Pg. 3, Paragraph 2.3 and Pg. 4, Fig. 4). Claim 2 merely defines the number of time points and separation time between time points, Claim 3 merely adds a third color channel to each luminescence image and Claims 4-5 merely define the first and second luminescent dyes. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3, 4, 5 and 11-13 are rejected under 35 U.S.C. § 102(a)(1) as being anticipated by Powless et al. (2016), cited in the IDS. Powless et al. teaches a method comprising; providing a blood sample (inherently comprising a plurality of white blood cells/WBCs), adding a luminescent dye (acridine orange) to the sample to stain the WBCs, placing the stained WBCs on a test surface (epi-fluorescence microscope) and recording a series of images over-time at time gates of 3-4, 5-6 and 7-8 minutes in a first intensity value (red) and second intensity value (green) channel (thereby obtaining a data series for each white blood cell) and, analyzing the data to classify the white blood cells into 3 predetermined categories based on three luminescence colors/intensities of a green/blue/red color space corresponding to lymphocyte/monocyte/granulocyte and counting the white blood cells (Pg. 3, Paragraph 2.2, Pg. 3, Paragraph 2.3 and Pg. 4, Paragraph 2.5 and Fig. 4 and Pg. 5, Fig. 5 and Pg. 7, Fig. 8), and reading on Claims 1, 3, 4, 5, 11, 12 and 13. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 2, 3, 4, 5 and 11-13 are rejected under 35 U.S.C. 103 as being unpatentable over Powless et al. (2016), cited in the IDS. The teachings of Powless et al. were discussed above. Powless et al. did not teach a method wherein the luminescence image series comprises at least 4 luminescence images, separated from each other by at least 5 seconds, as required by Claim 2. While the above cited reference does not specifically teach the claimed image number limitations and the time period between images, those of ordinary skill in the art before the effective filing date would recognize the number of images taken and the time period between images as an optimizable variable. In this instance, Powless teaches obtaining multiple images over time with a period of time between time gates. These are effective results based on the desired number of images at each time point. This is motivation for the ordinary artisan to practice or test the image number and time therebetween widely to determine those that are functional and optimal which would be inclusive or cover the instantly claimed ranges. Absent any teaching of criticality by the Applicant concerning the claimed image number and timing between images, it would be prima facie obvious that the ordinary artisan would recognize these limitations are an optimizable variable which can be met as a matter of routine optimization, see the MPEP at 2144.05 Il. B. There would have been a reasonable expectation of success in making this modification because the prior art teaches obtaining the same images over time at different time points and the determination of the optimal image number and timing between images by routine optimization was within the purview of those of ordinary skill in the art prior to the effective filing date. Claim(s) 1-5, 6 and 11-13 are rejected under 35 U.S.C. 103 as being unpatentable over Powless et al. (2016), as applied to Claims 1-5 and 11-13 above, and further in view of Sbalzarini et al. (2005), both cited in the IDS. The teachings of Powless et al. were discussed above. Powless et al. did not teach a method wherein analyzing the luminescence data series of each WBC comprises determining a trajectory over time of the WBC in a color space formed by said color channels, as required by Claim 6. Sbalzarini et al. teaches that in imaging a sequence of images at discrete time points can be used to ascertain the motion of physical particles in two-dimensions and the reconstruction of an ordered series of point locations over the recording time points of the individual images is called a trajectory (Pg. 183, Column 2, Lines 15-27) and that the automated detection of trajectories from image sequences provides knowledge which can be used to quantify particle motions, such as diffusion coefficients or transport velocities (Pg. 183, Column 2, Lines 1-6). It would have been obvious to those of ordinary skill in the art to modify the method of Powless et al. of serially imaging over time and distinguishing/analyzing luminescent stained white blood cells/WBC in a color space formed by three channels with the use of the method of Sbalzarini et al. of analyzing serial images to determine trajectories of the WBC as taught by Sbalzarini et al. because this would provide an additional data point for analysis of the imaged cells, that of motion over time. Those of ordinary skill in the art would have been motivated to make this modification because this would provide additional data which can be used to quantify the motion of the stained WBC. There would have been a reasonable expectation of success in making this modification because Powless et al. is drawn to the obtaining of serial images of stained cells over time and Sbalzarini et al. is drawn to the analysis of serial images of particles over time. Claim(s) 1-6, 7 and 11-13 are rejected under 35 U.S.C. 103 as being unpatentable over Powless et al. (2016) in view of Sbalzarini et al. (2005), both cited in the IDS, as applied to Claims 1-6 and 11-13 above, and further in view of Frade et al. (1997). The teachings of Powless et al. were discussed above. Powless et al. did not teach a method further comprising determining a Centroid-of-Trajectory for the WBC, as required by Claim 7. Frade et al. teaches that in imaging analysis if an object data point appears or disappears between two successive images over time this is a situation of collision (combination) or occlusion (separation) and the trajectory must be examined using the centroid of trajectory (an average of all points that make of the path or curve over time or space). It would have been obvious to those of ordinary skill in the art to modify the method of Powless et al. and Sbalzarini et al. of serially imaging over time and distinguishing/analyzing luminescent stained white blood cells/WBC including their trajectories, with the use of the method of Frade et al. of determining the Centroid-of-Trajectory for each imaged object as taught by Frade et al. because this would provide an additional data point for analysis of the imaged cells which can be used to distinguish between combined of separated imaged cells. Those of ordinary skill in the art would have been motivated to make this modification because this would provide additional data which can be used to quantify the individually stained and serially imaged WBC. There would have been a reasonable expectation of success in making this modification because Powless et al. is drawn to the obtaining of serial images of stained cells over time and Sbalzarini et al. and Frade et al. are both drawn to the analysis of serial images of particles/objects over time. No claims are allowed. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to PAUL C MARTIN whose telephone number is (571)272-3348. The Examiner can normally be reached Monday-Friday 12pm-8pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, Applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, Sharmila G Landau can be reached at (571) 272-0614. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /PAUL C MARTIN/ Examiner, Art Unit 1653 09/29/2026
Read full office action

Prosecution Timeline

Nov 15, 2024
Application Filed
Oct 21, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12746259
Mammalian Lung Spheroids and Lung Spheroid Cells and Uses Thereof
2y 5m to grant Granted Sep 29, 2026
Patent 12543667
Cultivation and Treatment of Plants for the Production of Plant-Derived Drugs
4y 3m to grant Granted Feb 10, 2026
Patent 12467915
TREATED DRIED BLOOD SAMPLE FOR DETECTION OF HEAVY METALS IN DRIED BLOOD
2y 1m to grant Granted Nov 11, 2025
Patent 12439925
ANTI-PATHOGENIC ACTIVITY OF A BIFUNCTIONAL PEPTIDOGLYCAN/CHITIN HYDROLASE
4y 6m to grant Granted Oct 14, 2025
Patent 12359241
COAGULOGEN-FREE CLARIFIED LIMULUS AMEBOCYTE LYSATE
3y 2m to grant Granted Jul 15, 2025
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
42%
Grant Probability
64%
With Interview (+21.7%)
3y 4m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 831 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month